{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:14:05Z","timestamp":1785852845274,"version":"3.56.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["ES\/P010873\/1"],"award-info":[{"award-number":["ES\/P010873\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016270","name":"Global Challenges Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Global Epidemiology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.gloepi.2021.100068","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T14:58:01Z","timestamp":1637679481000},"page":"100068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020"],"prefix":"10.1016","volume":"3","author":[{"given":"Houssein H.","family":"Ayoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghina R.","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiam","family":"Chemaitelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gloepi.2021.100068_bb0005","author":"John Hopkins University Coronavirus Resource Center"},{"key":"10.1016\/j.gloepi.2021.100068_bb0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(20)32009-2","article-title":"Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study","volume":"396","author":"Anand","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gloepi.2021.100068_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.4130","article-title":"Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020","author":"Havers","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.gloepi.2021.100068_bb0020","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41467-020-18272-4","article-title":"Substantial underestimation of SARS-CoV-2 infection in the United States","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"issue":"10247","key":"10.1016\/j.gloepi.2021.100068_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","volume":"396","author":"Stringhini","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.gloepi.2021.100068_bb0030","series-title":"The infection fatality rate of COVID-19 inferred from seroprevalence data","author":"Ioannidis","year":"2020"},{"issue":"6","key":"10.1016\/j.gloepi.2021.100068_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.gloepi.2021.100068_bb0040","doi-asserted-by":"crossref","first-page":"ofab221","DOI":"10.1093\/ofid\/ofab221","article-title":"SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar","volume":"8","author":"Al-Thani","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.gloepi.2021.100068_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102646","article-title":"SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals","volume":"24","author":"Coyle","year":"2021","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.gloepi.2021.100068_bb0050","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3201\/eid2705.204365","article-title":"Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar","volume":"27","author":"Jeremijenko","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.gloepi.2021.100068_bb0055","doi-asserted-by":"crossref","first-page":"05005","DOI":"10.7189\/jogh.11.05005","article-title":"Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19","volume":"11","author":"Ayoub","year":"2021","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.gloepi.2021.100068_bb0060","doi-asserted-by":"crossref","first-page":"18182","DOI":"10.1038\/s41598-021-97606-8","article-title":"SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar","volume":"11","author":"Seedat","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.gloepi.2021.100068_bb0065","author":"World Health Organization"},{"key":"10.1016\/j.gloepi.2021.100068_bb0070","author":"World Health Organization"},{"issue":"1","key":"10.1016\/j.gloepi.2021.100068_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-85428-7","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"11","author":"Abu-Raddad","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.gloepi.2021.100068_bb0080","article-title":"Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months","volume":"88","author":"Abu-Raddad","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.gloepi.2021.100068_bb0085","article-title":"Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting","volume":"ciaa1846","author":"Abu-Raddad","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.gloepi.2021.100068_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040428","article-title":"Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February\u201318 April 2020","volume":"10","author":"Al Kuwari","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.gloepi.2021.100068_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bmjinnov-2021-000677","article-title":"Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses","volume":"7","author":"Ayoub","year":"2021","journal-title":"BMJ Innov"},{"key":"10.1016\/j.gloepi.2021.100068_bb0100","article-title":"Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting","author":"Nasrallah","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.gloepi.2021.100068_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.gloepi.2021.100068_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B. 1.1. 7 and B. 1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.gloepi.2021.100068_bb0115","first-page":"1","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.gloepi.2021.100068_bb0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijid.2021.09.006","article-title":"Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar","volume":"112","author":"Hasan","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.gloepi.2021.100068_bb0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2021.9970","article-title":"Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar","volume":"326","author":"Bertollini","year":"2021","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.gloepi.2021.100068_bb0130","doi-asserted-by":"crossref","first-page":"taab083","DOI":"10.1093\/jtm\/taab083","article-title":"Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses","volume":"28","author":"Abu-Raddad","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.gloepi.2021.100068_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.145608","article-title":"COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar","volume":"774","author":"Saththasivam","year":"2021","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.gloepi.2021.100068_bb0140","article-title":"One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar","author":"Benslimane","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.gloepi.2021.100068_bb0145","article-title":"COVID-19 risk score as a public health tool to guide targeted testing: a demonstration study in Qatar","author":"Abu-Raddad","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.gloepi.2021.100068_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2) variant in Qatar","author":"Tang","year":"2021","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.gloepi.2021.100068_bb0155","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.2021.19623","article-title":"Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar","volume":"326","author":"Abu-Raddad","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.gloepi.2021.100068_bb0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","author":"Chemaitelly","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.gloepi.2021.100068_bb0165","article-title":"Severity, criticality, and fatality of the SARS-CoV-2 Beta variant","author":"Abu-Raddad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gloepi.2021.100068_bb0170","article-title":"Characterizing key attributes of the epidemiology of COVID-19 in China: model-based estimations","volume":"100042","author":"Ayoub","year":"2020","journal-title":"Global Epidemiol"},{"issue":"8","key":"10.1016\/j.gloepi.2021.100068_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237959","article-title":"Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide","volume":"15","author":"Ayoub","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.gloepi.2021.100068_bb0180","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-020-0962-9","article-title":"Age-dependent effects in the transmission and control of COVID-19 epidemics","volume":"26","author":"Davies","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.gloepi.2021.100068_bb0185","article-title":"Age specificity of cases and attack rate of novel coronavirus disease (COVID-19)","author":"Mizumoto","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.gloepi.2021.100068_bb0190","author":"United Nations Department of Economic and Social Affairs Population Dynamics"},{"key":"10.1016\/j.gloepi.2021.100068_bb0195","author":"WHO Coronavirus Disease (COVID-19) Dashboard"},{"issue":"10136","key":"10.1016\/j.gloepi.2021.100068_bb0200","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0140-6736(18)30994-2","article-title":"Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016","volume":"391","author":"Fullman","year":"2018","journal-title":"The Lancet"},{"issue":"20","key":"10.1016\/j.gloepi.2021.100068_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17207560","article-title":"Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients","volume":"17","author":"Faes","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.gloepi.2021.100068_bb0210","author":"COVID-19 Clinical Information Network (CO-CIN)"},{"issue":"4","key":"10.1016\/j.gloepi.2021.100068_bb0215","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(20)30984-1","article-title":"Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study","volume":"21","author":"Davies","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.gloepi.2021.100068_bb0220","author":"Centers for Disease Control and Prevention"},{"issue":"1","key":"10.1016\/j.gloepi.2021.100068_bb0225","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33706","article-title":"Estimation of US SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths using seroprevalence surveys","volume":"4","author":"Angulo","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gloepi.2021.100068_bb0230","author":"World Health Organization"},{"key":"10.1016\/j.gloepi.2021.100068_bb0235","series-title":"\u00ae, The Language of Technical Computing","author":"MATLAB","year":"2019"},{"issue":"10228","key":"10.1016\/j.gloepi.2021.100068_bb0240","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"issue":"6505","key":"10.1016\/j.gloepi.2021.100068_bb0245","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.abc6810","article-title":"A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2","volume":"369","author":"Britton","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.gloepi.2021.100068_bb0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.gloepi.2021.100068_bb0255","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"6530","key":"10.1016\/j.gloepi.2021.100068_bb0260","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.abf2946","article-title":"Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK","volume":"371","author":"du Plessis","year":"2021","journal-title":"Science"},{"issue":"6538","key":"10.1016\/j.gloepi.2021.100068_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.gloepi.2021.100068_bb0270","article-title":"Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study","volume":"372","author":"Challen","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.gloepi.2021.100068_bb0275","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries","volume":"26","author":"Funk","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.gloepi.2021.100068_bb0280","article-title":"Can the COVID-19 pandemic still be suppressed? Putting essential pieces together","volume":"4","author":"Mumtaz","year":"2020","journal-title":"J Global Health Rep"},{"key":"10.1016\/j.gloepi.2021.100068_bb0285","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijid.2020.09.1464","article-title":"A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates","volume":"101","author":"Meyerowitz-Katz","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.gloepi.2021.100068_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003189","article-title":"Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: a modeling study in Hubei, China, and six regions in Europe","volume":"17","author":"Hauser","year":"2020","journal-title":"PLoS Med"},{"issue":"6500","key":"10.1016\/j.gloepi.2021.100068_bb0295","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.gloepi.2021.100068_bb0300","first-page":"30243","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.gloepi.2021.100068_bb0305","series-title":"Report 34: COVID-19 infection fatality ratio: Estimates from Seroprevalence Imperial College London (29-10-2020)","author":"Brazeau","year":"2020"},{"issue":"1","key":"10.1016\/j.gloepi.2021.100068_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/biomed1010005","article-title":"Estimates of the COVID-19 infection fatality rate for 48 African countries: a model-based analysis","volume":"1","author":"Onovo","year":"2021","journal-title":"BioMed"},{"issue":"2","key":"10.1016\/j.gloepi.2021.100068_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246772","article-title":"Estimation of the fraction of COVID-19 infected people in U.S. states and countries worldwide","volume":"16","author":"Noh","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gloepi.2021.100068_bb0320","author":"SeroTracker"},{"issue":"6","key":"10.1016\/j.gloepi.2021.100068_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252617","article-title":"Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis","volume":"16","author":"Bobrovitz","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gloepi.2021.100068_bb0330","article-title":"Estimating under-recognized covid-19 deaths, united states, March 2020-May 2021 using an excess mortality modelling approach","volume":"1","author":"Iuliano","year":"2021","journal-title":"Lancet Region Health-Am"},{"key":"10.1016\/j.gloepi.2021.100068_bb0335","author":"World Health Organization"},{"key":"10.1016\/j.gloepi.2021.100068_bb0340","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.gloepi.2021.100068_bb0345","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69336","article-title":"Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset","volume":"10","author":"Karlinsky","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.gloepi.2021.100068_bb0350","author":"Estimation"},{"key":"10.1016\/j.gloepi.2021.100068_bb0355","author":"Tableau"}],"container-title":["Global Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590113321000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590113321000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:48:49Z","timestamp":1762912129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590113321000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":71,"alternative-id":["S2590113321000225"],"URL":"https:\/\/doi.org\/10.1016\/j.gloepi.2021.100068","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.24.21250396","asserted-by":"object"}]},"ISSN":["2590-1133"],"issn-type":[{"value":"2590-1133","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020","name":"articletitle","label":"Article Title"},{"value":"Global Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gloepi.2021.100068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100068"}}